A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Dec 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 16 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top